NASDAQ:TIL - Nasdaq - US45783C2008 - Common Stock - Currency: USD
NASDAQ:TIL (5/13/2025, 2:42:01 PM)
13.17
-0.51 (-3.73%)
The current stock price of TIL is 13.17 USD. In the past month the price decreased by -8.98%. In the past year, price increased by 18.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.39 | 334.14B | ||
AMGN | AMGEN INC | 13.08 | 146.05B | ||
GILD | GILEAD SCIENCES INC | 13.2 | 127.15B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.50B | ||
REGN | REGENERON PHARMACEUTICALS | 12.87 | 61.55B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.51B | ||
ARGX | ARGENX SE - ADR | 91.99 | 32.97B | ||
ONC | BEIGENE LTD-ADR | 5.54 | 24.04B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.89B | ||
NTRA | NATERA INC | N/A | 20.73B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.40B | ||
BIIB | BIOGEN INC | 7.82 | 18.12B |
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2021-03-19. The firm seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.
INSTIL BIO INC
3963 Maple Avenue, Suite 350
Dallas TEXAS 75219 US
CEO: Bronson Crouch
Employees: 49
Phone: 19724993350
The current stock price of TIL is 13.17 USD. The price decreased by -3.73% in the last trading session.
The exchange symbol of INSTIL BIO INC is TIL and it is listed on the Nasdaq exchange.
TIL stock is listed on the Nasdaq exchange.
8 analysts have analysed TIL and the average price target is 115.94 USD. This implies a price increase of 780.33% is expected in the next year compared to the current price of 13.17. Check the INSTIL BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INSTIL BIO INC (TIL) has a market capitalization of 86.40M USD. This makes TIL a Micro Cap stock.
INSTIL BIO INC (TIL) currently has 49 employees.
INSTIL BIO INC (TIL) has a support level at 13.07 and a resistance level at 14.49. Check the full technical report for a detailed analysis of TIL support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TIL does not pay a dividend.
INSTIL BIO INC (TIL) will report earnings on 2025-08-11, before the market open.
INSTIL BIO INC (TIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.39).
The outstanding short interest for INSTIL BIO INC (TIL) is 9.33% of its float. Check the ownership tab for more information on the TIL short interest.
ChartMill assigns a fundamental rating of 2 / 10 to TIL. TIL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months TIL reported a non-GAAP Earnings per Share(EPS) of -11.39. The EPS increased by 52.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.13% | ||
ROE | -43.75% | ||
Debt/Equity | 0.5 |
ChartMill assigns a Buy % Consensus number of 83% to TIL. The Buy consensus is the average rating of analysts ratings from 8 analysts.